Ablative fractional laser-assisted treatments for keratinocyte carcinomas and its precursors – Clinical review and future perspectives Review


Authors: Erlendsson, A. M.; Olesen, U. H.; Haedersdal, M.; Rossi, A. M.
Review Title: Ablative fractional laser-assisted treatments for keratinocyte carcinomas and its precursors – Clinical review and future perspectives
Abstract: Keratinocyte carcinomas (KC) are the most common malignant human neoplasms. Although surgery and destructive approaches are first-line treatments, topical therapies are commonly used. Due to limited uptake of topical agents across the skin barrier, clearance rates are often sub-optimal. In pre-clinical investigations, ablative fractional laser (AFL)-assisted drug delivery has demonstrated improved uptake of topical drugs commonly used to treat KC. In 22 clinical trials, the effect of AFL-assisted treatments has been investigated for actinic keratosis (AK; n = 14), Bowen's disease (BD; n = 5), squamous cell carcinoma (n = 1), and basal cell carcinoma (n = 7). The most substantial evidence currently exists for AFL-assisted photodynamic therapy for the treatment of AK and BD. AFL improved 12-months follow-up clearance rates of photodynamic therapy from 45.0–51.0% to 78.5–84.8% for AK and from 50.0–55.3% to 87.0–87.5% for BD. AFL-assisted pharmacological therapy is a promising tool for optimizing topical treatments of KC and its precursor lesions. Future developments include AFL-assisted immune activation, changing drug administration route of systemic therapies, and utilizing drug chemo-combinations. © 2020
Keywords: squamous cell carcinoma; actinic keratosis; basal cell carcinoma; immunotherapy; drug administration; combination therapy; photodynamic therapy; non-melanoma skin cancer; drug delivery; topical delivery; actinic keratoses; bowen's disease; precursor lesions; immune activation; future perspectives; ablative fractional laser; laser-assisted drug delivery; non-surgical treatment; topical treatments
Journal Title: Advanced Drug Delivery Reviews
Volume: 153
ISSN: 0169-409X
Publisher: Elsevier Science, Inc.  
Date Published: 2020-01-01
Start Page: 185
End Page: 194
Language: English
DOI: 10.1016/j.addr.2020.01.001
PUBMED: 31923431
PROVIDER: scopus
DOI/URL:
Notes: Review -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Anthony Rossi
    233 Rossi